Cell And Gene Therapy Manufacturing Services Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Cell and Gene Therapy Manufacturing Services covers a range of outsourced capabilities including viral vector production, cell line development, process development, and commercial-scale fill-finish operations tailored to advanced therapy medicinal products. The market in 2025 is positioned at roughly $10.09 billion, building from an estimated $5.9-8.1 billion base in 2023-2024 across various research assessments.

• •Research firm 2025 size estimates range from approximately $5.9 billion to $17 billion, reflecting differences in market boundaries and scope
• •Projected 2030-2032 market values span from roughly $19.7 billion to over $47 billion depending on forecast methodology and period
• •Multiple published reports converge on a compound annual growth rate in the 16-19% range through 2032, with longer-horizon studies citing even higher rates

A robust and expanding clinical pipeline of cell and gene therapies, particularly in oncology, rare genetic disorders, and autoimmune conditions, is the primary catalyst for manufacturing demand. The technical and capital-intensive nature of viral vector and cell processing has led most biotechnology and pharmaceutical companies to outsource manufacturing rather than build internal capacity.

• •Regulatory approvals of transformative therapies such as CAR-T treatments and gene therapies for hemophilia and sickle cell disease have validated manufacturing demand at commercial scale
• •Small and mid-sized biotech firms lacking internal manufacturing infrastructure represent a significant and growing customer base for contract development and manufacturing organizations
• •Advances in allogeneic (off-the-shelf) cell therapies and next-generation viral vector platforms are expected to further expand manufacturing volume requirements

The market is typically segmented by therapy type, cell therapy manufacturing services and gene therapy manufacturing services, as well as by service phase covering process development, clinical manufacturing, and commercial manufacturing. Geographic distribution is led by North America, home to the largest concentration of biotechnology companies and regulatory-approved advanced therapies.

• •North America dominates the market, supported by a dense biopharmaceutical ecosystem, favorable regulatory pathways at the FDA, and strong clinical trial activity
• •Europe represents the second-largest region, with the EMA playing a central role in approving innovative therapies and the UK maintaining a significant gene therapy research base
• •The Asia-Pacific region is emerging as a growth market, driven by lower manufacturing costs, increasing clinical trial activity, and government initiatives supporting advanced therapy development in countries including China, Japan, and South Korea

What are the recent trends and outlook?

Manufacturing innovation is a critical industry priority, with growing emphasis on process intensification, closed-system processing, and modular facility designs to improve yield and reduce contamination risk. The market trajectory will be shaped by therapy commercialization success, pricing and reimbursement dynamics, and continued capacity expansion by contract manufacturing organizations.

• •Single-use and modular manufacturing technologies are gaining adoption to enable faster facility build-out and greater production flexibility for multi-product facilities
• •The pipeline of late-stage cell and gene therapies approaching approval creates both a significant commercial opportunity and a potential capacity bottleneck that the manufacturing services sector must address
• •Emerging modalities including in vivo gene therapies, engineered cell therapies for solid tumors, and combined modality approaches are expected to create new manufacturing complexity and drive further market expansion